Cue Biopharma (NASDAQ:CUE) Shares Up 9% – What’s Next?

Cue Biopharma, Inc. (NASDAQ:CUE) shares rose 9% during trading on Friday . The company traded as high as $0.3067 and last traded at $0.3020. Approximately 1,314,008 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 2,017,854 shares. The stock had previously closed at $0.2770.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cue Biopharma in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Cue Biopharma Price Performance

The company’s 50-day simple moving average is $0.46 and its 200-day simple moving average is $0.66. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.66. The stock has a market capitalization of $23.78 million, a price-to-earnings ratio of -0.66 and a beta of 1.47.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. Cue Biopharma had a negative return on equity of 271.67% and a negative net margin of 530.75%.The business had revenue of $2.15 million during the quarter, compared to the consensus estimate of $2.29 million. Research analysts forecast that Cue Biopharma, Inc. will post -0.76 earnings per share for the current fiscal year.

Institutional Trading of Cue Biopharma

Several large investors have recently modified their holdings of CUE. GC Wealth Management RIA LLC bought a new position in Cue Biopharma in the 2nd quarter valued at about $2,273,000. Boothbay Fund Management LLC acquired a new position in Cue Biopharma during the third quarter valued at approximately $439,000. Angeles Wealth Management LLC acquired a new stake in shares of Cue Biopharma in the 2nd quarter valued at $82,000. Squarepoint Ops LLC acquired a new stake in shares of Cue Biopharma in the 3rd quarter valued at $62,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares during the last quarter. 35.04% of the stock is owned by institutional investors and hedge funds.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.